Dr. Fathi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-1124Fax+1 617-724-1126
Education & Training
- Harvard School of Public HealthMasters, Epidemiology, 2012 - 2014
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
- Massachusetts General HospitalResidency, Internal Medicine, 2004 - 2007
- Yale School of MedicineClass of 2004
- Yale UniversityBS, 1996 - 2000
Certifications & Licensure
- MA State Medical License 2006 - 2024
- MD State Medical License 2007 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Alisertib for Acute Myeloid Leukemia Start of enrollment: 2013 Apr 01
- A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
- Brentuximab Vedotin + Re-induction Chemotherapy for AML Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 93 citationsThe use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24 - 423 citationsTargeting FTO Suppresses Cancer Stem Cell Maintenance and Immune EvasionRui Su, Lei Dong, Yangchan Li, Min Gao, Li Han
Cancer Cell. 2020-07-13 - 23 citationsAlisertib Plus Induction Chemotherapy in Previously Untreated Patients With High-Risk, Acute Myeloid Leukaemia: A Single-Arm, Phase 2 TrialAndrew M. Brunner, Traci M. Blonquist, Daniel J. DeAngelo, Malgorzata McMasters, Geoffrey Fell
The Lancet. Haematology. 2020-02-01
Journal Articles
- Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid LeukemiaAreej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
- A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AMLEytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Abstracts/Posters
- Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion StudyAmir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...Amir T. Fathi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- AML: Expert Guidance on Current Standards and New Directions in Patient Care61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- ORYZON Presents Preliminary Data from Ongoing Phase Ib FRIDA Trial with Iadademstat plus Gilteritinib in Relapsed/Refractory FLT3-Mut AML Patients at EHA-2024June 14th, 2024
- A Beacon of Hope: Exploring Immunotherapy for Bone CancerMay 11th, 2024
- Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHAMay 18th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: